TSC was originally developed in conjunction with the United States Office of Naval Research to treat multiple organ failure and its resulting mortality caused by low oxygen levels due to blood loss on the battlefield. Evolutions in research have led the Company to focus on addressing some of medicine’s most intractable and difficult-to-treat conditions involving cellular oxygen deficiency, or hypoxia, such as COVID-19, stroke, glioblastoma multiforme (“GBM”) brain cancer, and other conditions and diseases in which hypoxia is a critical factor presenting a significant treatment obstacle .
TSC has been shown to enhance the availability of oxygen in multiple animal models. It increased tissue oxygenation in rat models of cerebral ischemia (Brain Research, 2014) and has demonstrated functional benefit in animal models of acute lung injury and haemorrhagic shock.
The safety and tolerability of TSC has been evaluated in more than 150 patients in a range of clinical trials across several life-threatening conditions, including peripheral artery disease, glioblastoma multiform (a common brain cancer) and in acute stroke.
Given the unique mechanism of action, the substantial unmet medical need, and the clinically significant decrease in blood oxygen levels of many patients infected with SARS-CoV-2, Diffusion Pharmaceutical’s has recently begun investigation of TSC in patients with COVID-19.